Lantheus Holdings, Inc.
LNTHHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned May 28, 2026
Scan Results
Daily timeframe1 of 4 indicators bearish as of May 27
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. At a $6.45B market cap, Lantheus Holdings, Inc. ranks as a mid-cap company within healthcare. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.
Market Cap
$6.45B
Beta
-0.08
P/E (TTM)
23.65
P/E (Fwd)
15.54
EPS (TTM)
$4.19
EPS (Fwd)
$6.37
ROE
23.5%
ROA
8.2%
Cash
$498.6M
Total Debt
$625.8M
Free CF
$421.7M
52W Change
31.2%
Annual Financials
Cash vs Debt
On the balance sheet, LNTH has $498.6M in cash with $625.8M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company generates $421.7M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 23.5% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 8.2% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $425.2M (2021) to $1.54B (2025), reflecting a 263% increase over the period.
With a beta below 0.7, Lantheus Holdings, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing LNTH.